New York Blood Center   Report issue

Contributed to NME Academic/Hospital Phase 1 Phase 2 Phase 3
Founded: New York City NY United States (1964)

Organization Overview

First Clinical Trial
1993
NCT00212407
First Marketed Drug
2011
allogeneic hematopoietic stem cells (Hemacord)
First NDA Approval
2011
allogeneic hematopoietic stem cells (Hemacord)
Last Known Activity
2020

Timeline

NOW
  • Now

Alternative names

New York Blood Center | New York Blood Center, Inc. | New York Blood Centre | Shi, Patricia, M.D.

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Anemia, Aplastic (Phase 1)

Anemia, Sickle Cell (Phase 1)

Coronavirus Infections (Phase 2)

Genetic Diseases, Inborn (Phase 1)

HIV Infections (Phase 1)

Leukemia (Phase 3)

Leukemia, Myelogenous, Chronic, BCR-ABL Positive (Phase 3)

Leukemia, Myeloid (Phase 3)

Leukemia, Myeloid, Acute (Phase 3)

Lymphoma (Phase 3)

Myelodysplastic Syndromes (Phase 3)

Precursor Cell Lymphoblastic Leukemia-Lymphoma (Phase 3)

Preleukemia (Phase 1)

Severe Acute Respiratory Syndrome (Phase 2)

Transfusion Reaction (Phase 1)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 13
  • # of Trial APIs: 15